Bao Rui Announces Completion of Acquisition of Biologics CDMO Operations in Maryland, USA

1. Date of Event: 07/02/2026 2. Company Name: Bao Rui Pharmaceutical Co., Ltd. 3. Relationship with Company (Please enter '本公司' or 'Subsidiary'):本公司 (This Company) 4. Cross-shareholding Ratio: Not applicable. 5. Reason for Occurrence: Today, the Company fulfilled the payment of the acquisition price, and in accordance with the mutual agreement, the transaction closed as of June 30 Eastern Time. Upon completion, the Company’s wholly-owned subsidiary, Bora Biologics USA, LLC, acquired the divested biologics CDMO operating assets from MacroGenics (NASDAQ: MGNX), including the large-molecule manufacturing plant in Rockville, Maryland, and the warehouse center in Frederick. Simultaneously, the Company has entered into a long-term CDMO service agreement with MacroGenics. This acquisition will help establish a reliable U.S.-based biologics manufacturing platform, creating a fully integrated, end-to-end biologics contract development and manufacturing platform spanning drug substance and drug product capabilities, strengthening global CDMO footprint and enhancing international visibility. 6. Response Measures: None. 7. Other Matters to be Disclosed (If the subject of the event or resolution is a publicly listed company or above, this material information also meets the criteria under Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act regarding matters significantly affecting shareholder rights or securities prices): None.